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Supplementary Table S1: Characteristics of 21 children who were clinically detected  
 
Sex Gestation (weeks) 
Clinical 
presentation 
Bloodspot 
TSH 
(mU/L) 
Serum 
TSH 
(mU/L) 
Began 
treatment Outcome at 3 years 
F ≥37 Jaundice 3 9 yes Confirmed permanent CH (trial off therapy) 
F ≥37 Congenital anomaly 1 - yes Confirmed permanent CH (trial off therapy) 
F ≥37 
Suspected before 
screen; Family 
history 
7 15 yes Confirmed permanent CH (high dose thyroxine) 
M <32 Sick neonate 1 - yes Confirmed permanent CH (trial off therapy) 
F 32-37 Jaundice; Family history 3 13 yes Probably permanent CH 
M <32 Jaundice 1 13 yes Probably permanent CH 
M ≥37 Jaundice 5 15 yes Probably permanent CH 
F ≥37 Jaundice 5 14 yes Probably permanent CH 
M 32-37 Congenital anomaly 4 9 yes Probably permanent CH 
M <32 Sick neonate 1 29 yes Probably permanent CH 
F <32 Congenital anomaly 4 47 yes Probably permanent CH 
M 32-37 Suspected before screen; Sick neonate 8 16 yes Probably permanent CH 
F ≥37 
Suspected before 
screen; Congenital 
anomaly 
40 100 yes Probably permanent CH 
M ≥37 
Suspected before 
screen; Family 
history 
20 98 yes Probably permanent CH 
M <32 Congenital anomaly 2 4 yes Not CH (trial off therapy) 
M 32-37 Congenital anomaly - 14 yes Not CH (trial off therapy) 
F ≥37 Jaundice 4 34 yes Not CH (trial off therapy) 
F ≥37 Congenital anomaly - 16 yes Not CH (clinical evaluation) 
M ≥37 Poor growth - 55 yes Not CH (clinical evaluation) 
F 32-37 Congenital anomaly - 16 yes Not CH (clinical evaluation) 
F <32 Sick neonate 14 21 no Not CH (clinical evaluation) 
 
Abbreviations TSH thyroid stimulating hormone; M male; F female; CH congenital hypothyroidism 
  
Supplementary Table S2: Screening programme performance at different test cut-offs 
for a hypothetical population of 100,000 infants 
 
 
Screening performance – comparing cut-offs* 
  Group 1**  
Actual population screened 
n=315944 
Group 2** 
Actual population 
screened n=125886 
Group 3** 
Actual population 
screened n=252028 
TSH (mU/L) ≥6 ≥8 ≥10 >20 ≥8 ≥10 >20 ≥10 >20 
Standardised population 
of screened infants (n) 100,000
† 100,000† 100,000† 
Expected cases (n) 57 57# 57## 
Positive screen result (n) 90 63 55 44 75 61 51 67 54 
True positives (n) 56 49 45 38 55 48 41 48 43 
False positives (n) 34 14 10 6 20 13 10 19 11 
Negative screen result (n) 99910 99937 99945 99956 99925 99939 99949 99933 99946 
False negatives (n) 1 8 12 19 2 9 16 9 14 
True negatives (n) 99909 99929 99933 99937 99923 99930 99933 99924 99932 
Detection rate (%) 98.2% 86.0% 79.0% 66.7% 96.5% 84.2% 71.9% 84.2% 75.4% 
PPV (%) 62.2% 77.8% 81.8% 86.4% 73.3% 78.7% 80.4% 71.6% 79.3% 
False positive rate (%) 0.03% 0.01% 0.01% 0.01% 0.02% 0.01% 0.01% 0.02% 0.01% 
 
Notes *based on 13 newborn screening laboratories in England; screening programme coverage for 2011-2012 
was 86%; PPV=positive predictive value;  
Group 1 included 6 laboratories of which 1 used a threshold of ≥5mU/L and 5 used a threshold of ≥6mU/L; 
Group 2 included 3 laboratories, all using a threshold of ≥8mU/L; Group 3 included 4 laboratories, all using a 
threshold of ≥10mU/L. As exact values for TSH are not provided for negative screen results, these were 
reported only as ‘negative’, therefore estimates can only be made of screening performance at a cut-off TSH 
≥6mU/L for Group 1 (and not for Groups 2 and 3). 
** The percentage who were of white ethnicity were 68% in Group 1, 79% in Group 2 and 70% in Group 3 
† 100,000 live births directly standardised15 using the actual English population profile (by sex, ethnicity and 
gestation) for 2011-2012 
# 1 additional false negative to account for case detected at cut-off of 6 in Group 1 
## 2 additional false negatives to account for cases detected at cut-off of 6 in Group 1 
Total number of babies screened (Tables S1 and S2) is greater (n=110 [0.01% of 800,000) than the total 
English live births reported in Table 3 as the data sources varied. This is because the denominator in Table 3 
was from monthly figures provided by the Office for National Statistics for live births occurring in England, while 
the ‘screened population’ denominator in Tables S1 and S2 was provided by the screening programme from 
annual reporting of babies screened in England. The minor discrepancy may be due to several reasons, 
including some births occurring outside England but being screened in England in border areas, or inaccuracies 
in national reporting systems. The relevant denominator was therefore used for each table. 
 
  
Supplementary Table S3: Children who would have been missed at the national 
screening cut-off TSH≥10mU/L 
 
 Gestation Bloodspot TSH (mU/L) 
Serum 
TSH 
(mU/L) 
SerumT4 
(pmol/L) 
Confounding 
factors Scan CH confirmation 
Children who would be detected at TSH≥6mU/L but not at TSH≥8mU/L 
A ≥37 weeks 6.3 50.5 13.7 Congenital syndrome Abnormal Agenesis (scan) 
B ≥37 weeks 6.8 16.4 17.0 None Normal Trial-off therapy 
C ≥37 weeks 7.8 22.0 NK None Abnormal Trial-off therapy 
D ≥37 weeks 7.0 64.2 14.4 None Abnormal Trial-off therapy 
Children who would be detected at TSH≥8mU/L but not at TSH≥10mU/L 
E <32 weeks 8.0 NK NK None Normal Trial-off therapy 
F ≥37 weeks 8.0 51.8 19.0 None Abnormal High dose thyroxine 
G <32 weeks 9.3 NK 3.6 None Normal Trial-off therapy 
H ≥37 weeks 9.3 20.3 12.4 None Abnormal Trial-off therapy 
J 32-37 weeks 9.9 17.6 NK None No scan High dose thyroxine 
K ≥37 weeks 9.9 16.0 13.0 None Abnormal High dose thyroxine 
 
Notes Total screened population (Groups 1 and 2) of 441830 newborns. TSH and T4 levels were 
those recorded at initial clinical referral after a positive screening result. Abnormal scans showed avid 
or poor uptake and were suggestive of dyshormonogenesis, except for the scan confirming agenesis. 
Abbreviations TSH thyroid stimulating hormone; CH congenital hypothyroidism; NK not known 
(information not found in medical records) 
 
 
